Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03487913
Recruitment Status : Completed
First Posted : April 4, 2018
Last Update Posted : February 20, 2020
Sponsor:
Information provided by (Responsible Party):
Palladio Biosciences

Brief Summary:
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney Disease subjects with chronic kidney disease in stages CKD1, CKD2 or CKD3.

Condition or disease Intervention/treatment Phase
Autosomal Dominant Polycystic Kidney Disease Drug: Lixivaptan Phase 2

Detailed Description:

Therapeutic interventions aimed at counterbalancing the effect of vasopressin and/or normalizing intracellular levels of cAMP may be effective in delaying disease progression in autosomal dominant polycystic kidney disease (ADPKD).

The primary objectives of this study in subjects with ADPKD are:

  • To characterize the safety and tolerability of lixivaptan following multiple doses in ADPKD subjects with relatively preserved kidney function (chronic kidney disease CKD1 and CKD2) and moderately impaired renal function (CKD3).

The secondary objectives of this study are:

  • To characterize the PK profile of lixivaptan and its major metabolites following multiple doses of lixivaptan in ADPKD subjects with relatively preserved kidney function (CKD1 and CKD2) and moderately impaired renal function (CKD3).
  • To characterize the pharmacodynamic effect of lixivaptan on urine output, urine osmolality, total kidney volume, serum vasopressin, and serum creatinine following multiple doses of lixivaptan in ADPKD subjects with relatively preserved kidney function (CKD1 and CKD2) and moderately impaired renal function (CKD3).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Actual Study Start Date : September 14, 2018
Actual Primary Completion Date : December 2, 2019
Actual Study Completion Date : February 11, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: High dose
Oral lixivaptan
Drug: Lixivaptan
Oral vasopressin V2 receptor antagonist
Other Name: VPA-985

Experimental: Low dose
Oral lixivaptan
Drug: Lixivaptan
Oral vasopressin V2 receptor antagonist
Other Name: VPA-985




Primary Outcome Measures :
  1. Number of study participants with treatment-emerging adverse events [ Time Frame: 35 days ]
    The number of study participants who experience treatment-emerging adverse events during the study will be measured.


Secondary Outcome Measures :
  1. Evaluation of the maximum observed plasma concentration of Lixivaptan in ADPKD patients [ Time Frame: 10 days ]
    The pharmacokinetic parameter Cmax will be used to measure the highest concentration of Lixivaptan in plasma after multiple doses of drug

  2. Evaluation of the area under the concentration-time curve from time 0 until the last quantifiable concentration of Lixivaptan in ADPKD patients [ Time Frame: 10 days ]
    The pharmacokinetic parameter AUC0-last for Lixivaptan, calculated using the linear trapezoidal rule for increasing values and the log trapezoidal rule for decreasing values, will be measured and summarized by dose

  3. Mean change from baseline in trough urine osmolality after 7 days of treatment with Lixivaptan in ADPKD patients [ Time Frame: 7 days ]
    Spot urine osmolality at trough (mOsm/kg) will be determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline) and Day 7.

  4. Mean change from baseline in serum creatinine after 7 days of treatment with Lixivaptan in ADPKD patients [ Time Frame: 7 days ]
    Serum creatinine (mg/dL) will be determined from plasma samples collected immediately prior to morning dosing for Day 1 (Baseline) and Day 7.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, between 18 and 65 years of age at the time of screening
  • Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 with eGFR calculated by the CKD EPI equation
  • Diagnosed with ADPKD by modified Ravine criteria
  • Considered by Investigator to be in good health relative to underlying CKD status and clinically stable with respect to underlying CKD

Exclusion Criteria:

  • Known sensitivity or idiosyncratic reaction to lixivaptan, its related compounds such as benzazepines (e.g., tolvaptan, conivaptan, benazepril, fenoldopam, or mirtazapine), or any compound listed as being present in the study formulation
  • Women who are pregnant or breast feeding
  • Subjects have taken tolvaptan, oral or intravenous antibiotics, or any investigational drug or used an investigational device within 30 days or 5 half-lives, whichever is longer, prior to first study dose
  • Subject has a transplanted kidney, or absence of a kidney
  • Subjects with clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia)
  • Subjects with clinically significant liver disease, or clinically significant liver function abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline
  • Subjects with any clinically significant concomitant disease or condition other than ADPKD (including treatment for such conditions) that, in the opinion of the Investigator, could either interfere with the study drug or pose an unacceptable risk to the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03487913


Locations
Layout table for location information
United States, California
Palladio Biosciences Clinical Site
Los Angeles, California, United States, 90022
United States, Florida
Palladio Biosciences Clinical Site
Jacksonville, Florida, United States, 32216
Palladio Biosciences Clinical Site
Miami, Florida, United States, 33155
Palladio Biosciences Clinical Site
Miami, Florida, United States, 33165
Palladio Biosciences Clinical Site
Palmetto Bay, Florida, United States, 33157
Palladio Biosciences Clinical Site
Tampa, Florida, United States, 33612
United States, Maryland
Palladio Biosciences Clinical Site
Baltimore, Maryland, United States, 21201
United States, Minnesota
Palladio Biosciences Clinical Site
Rochester, Minnesota, United States, 55902
United States, Missouri
Palladio Biosciences Clinical Site
Kansas City, Missouri, United States, 64111
United States, New York
Palladio Biosciences Clinical Site
Laurelton, New York, United States, 11413
United States, Pennsylvania
Palladio Biosciences Clinical Site
Indiana, Pennsylvania, United States, 15701
United States, Tennessee
Palladio Biosciences Clinical Site
Nashville, Tennessee, United States, 66160
United States, Utah
Palladio Biosciences Clinical Site
Salt Lake City, Utah, United States, 84115
Sponsors and Collaborators
Palladio Biosciences

Layout table for additonal information
Responsible Party: Palladio Biosciences
ClinicalTrials.gov Identifier: NCT03487913    
Other Study ID Numbers: PA-102
First Posted: April 4, 2018    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Kidney Diseases, Cystic
Abnormalities, Multiple
Congenital Abnormalities
Ciliopathies
Genetic Diseases, Inborn